Integration of complex in vitro models into preclinical drug development
Head Complex In Vitro Models, In Vitro/In Vivo Translation, Research, GlaxoSmithKline
I head the Complex In Vitro Models group in the R&D Platform Technology & Sciences organization at GlaxoSmithKline. I lead an integrated enterprise strategy for sustained, portfolio driven growth in R&D applications of human-relevant and translatable complex in vitro models (eg Spheroids, Organoids, MPS and bioprinting). Before coming to GSK I spent 11 years at Janssen BioTherapeutics in early biotherapeutic drug discovery in target discovery, drug validation and MOA studies applying complex cell-based assays across multiple therapeutic areas. My current focus at GSK is to improve predictive validity of early preclinical models leading to better characterized molecules, decreased R&D cycle time and a reduction in attrition.